Category Archives: News and Events

BriaCell Presents Benchmark Beating Survival and Clinical Benefit at AACR 2025; Advancements in Next Generation Bria-OTS+(TM) Development
April 28, 2025

Overall survival and clinical benefit in Phase 2 continue to outperform historical benchmarks, including very ...

BriaCell Therapeutics Announces Pricing of $13.8 million Public Offering
April 24, 2025

PHILADELPHIA and VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Confirms 100% Resolution of Lung Metastasis with Bria-OTS(TM)
April 24, 2025

(IMAGES BELOW) Complete resolution of lung metastasis confirmed at 4 month follow-up in hormone receptor ...

BriaCell Announces Four Clinical Data Presentations at ASCO 2025
April 23, 2025

PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

BriaCell Enrollment Pace Accelerating in Phase 3 Clinical Study in Advanced Metastatic Breast Cancer (Bria-ABC)
April 22, 2025

Over 75 patients enrolled in BriaCell’s pivotal Phase 3 study of Bria-IMT ™ plus immune ...

BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer
April 16, 2025

Median overall survival of 17.3 months in Bria-IMT™ treated patients with hormone receptor positive (HR+) ...

BriaCell’s Subsidiary, BriaPro, Develops Novel Antibodies to Anti-Cancer Target B7-H3
April 10, 2025

BriaPro is developing novel antibodies to B7-H3, a key cancer antigen and immune checkpoint Highly ...

BriaCell to Present Clinical and Preclinical Data at the 2025 AACR Conference
March 26, 2025

PHILADELPHIA and VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...

Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
March 20, 2025

The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell’s ...

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
February 5, 2025

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. ...

Skip to content